A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepressant-resistant major depression or patients with dysthymic disorder Estudio de Fase II, piloto, prospectivo, randomizado, doble ciego, de 12 semanas de duración para comparar la eficacia y seguridad de masitinib frente a placebo en el tratamiento de trastornos del estado de ánimo en pacientes con depresión mayor resistente a los antidepresivos o en pacientes con trastornos distímicos.

Trial Profile

A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepressant-resistant major depression or patients with dysthymic disorder Estudio de Fase II, piloto, prospectivo, randomizado, doble ciego, de 12 semanas de duración para comparar la eficacia y seguridad de masitinib frente a placebo en el tratamiento de trastornos del estado de ánimo en pacientes con depresión mayor resistente a los antidepresivos o en pacientes con trastornos distímicos.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2013

At a glance

  • Drugs Masitinib (Primary)
  • Indications Dysthymic disorder; Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top